Plasmid DNA Technology Platforms Transforming Gene Therapy

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology TOE depicts life sciences trends across plasmid DNA and DNA vaccine technologies. The role of plasmid DNA manufacturing in the pharmaceutical industry, especially in cancer immunotherapy, is illustrated across industry profiles and notable innovations in the field. The corresponding clinical trial scenario for DNA vaccines is depicted, along with the industry interactions.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology appl

Table of Contents

Plasmid DNA Technology Platforms Transforming Gene TherapyAdvancing Plasmid DNA and DNA Vaccine TechnologiesDNA Adjuvant Technology Granted US PatentPlasmid DNA Bioproduction Creates New Horizons in Human HealthEfficient and Scalable DNA Production for Critical Emerging DiseasesInvestigational Platform for Cancer ImmunotherapyClinical Trials Perspective and Industry InteractionsClinical Trials PerspectiveClinical Trials Perspective (continued)Clinical Trials Perspective (continued)Industry Interactions

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.